Translating complex carbohydrate chemistries into unique, leading-edge products that enable researchers to explore and exploit glycobiology applications that promote human health.
Sussex Research Laboratories Inc., a global leader in carbohydrate synthesis and the translation of complex carbohydrate chemistries into unique, leading-edge products that enable researchers to explore and exploit glycomics applications that promote human health., is pleased to announce the appointment of Dr. Corwin Nycholat to its Scientific Advisory Board.
Many critical roles of glycan elements on cell surface proteins and those bound to circulatory proteins are being recognized. Carbohydrates on proteins mediate a host of biological events including cell adhesion, immune system function, fertilization, cellular targeting as well as protein transport, stabilization, and half-life.
Tris-GalNAc: Triantennary GalNAc-β-Alanine-PEG3-Biotin
Sussex Research Laboratories Inc. has been working in the carbohydrate field for over two decades and have applied our synthetic strategies to seemingly countless problems. We have enabled application of complex carbohydrate systems for drug discovery, drug delivery, drug targeting, carbohydrate-based vaccine development, immunotherapy, therapeutic enhancement and diagnostic/bio-analytical assay development.
Drug Targeting – GalNAc
Targeted drug delivery of therapeutic payloads using N-acetylgalactosamine (GalNAc) conjugates that bind to Ashwell-Morell Receptors (asialoglycoprotein receptors or ASGPR) found in liver hepatocytes has become a leading delivery approach particularly for therapeutic oligonucleotides. Read more…
Vaccine Development – Polysaccharide Chemistry
Bacteria are highly glycosylated pathogens. Glycoconjugate vaccines have been proven to be a successful strategy to prevent infectious diseases with the global pneumococcal vaccine market estimated to be > $8 billion (USD) in 2021. Read more…
REQUEST A QUOTATION
Cancer – Glycans
It is well established that abnormal glycosylation on tumour cells compared to healthy cells is a hallmark of cancer and common to all cancers. Moreover, specific glycans on cell surface proteins actively drive tumour development and progression. New frontiers in drug discovery & development are being realized thanks to discoveries being made in glycobiology. Read more…
Monoclonal Antibody Development – Glycopeptides & Glycoconjugate Antigens
Therapeutic antibodies have become the predominant class of new drugs developed in recent years. Whether it is the antigen required to screen antibodies or to produce an antibody, we have the synthetic tools to produce carbohydrate antigens and their respective carrier protein conjugates. Read more…
Sussex Research Laboratories Inc. Official Sponsor of Glyconet’s Canadian Glycomics Symposium 2023
May 11, 2023
Sussex Research Laboratories Inc., leading GalNAc and glycopeptide specialist, is excited to announce sponsorship of GlycoNet’s Canadian Glycomics Symposium hosted in Edmonton, Alberta, Canada from May 10-12. For more information about CGS 2023 – visit https://symposium.canadianglycomics.ca/ For over 25...
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2023: Oligonucleotide & Peptide Therapeutics
April 27, 2023
Sussex Research Laboratories Inc., leading GalNAc and glycopeptide specialist, is excited to announce sponsorship of TIDES USA 2023: Oligonucleotide & Peptide Therapeutics. Visit us at booth 416 in San Diego, CA, USA and meet our CEO, Dr. Brady Clark,...
Sussex Research Laboratories Inc. to Attend the Landmark Glycobiology Symposium (LGS)
March 28, 2023
Sussex Research Laboratories Inc., leading GalNAc and glycopeptide specialist, is excited to celebrate Prof. James C. Paulson and his contributions in the field of glycobiology at the Landmark Glycobiology Symposium (LGS) in San Diego, California, USA! Our newly appointed...